Thus, NT-proBNP may be increased as a consequence of concomitant septic cardiomyopathy, type 2 AMI or drug toxicity, however, our study group recently suggested NT-proBNP levels did not differ among sepsis survivors and non-survivors, alongside with a poor predictive accuracy with regard to 30-day all-cause mortality in 162 patients with sepsis and septic shock [20,44]. This evidence concerns the gene NPPB and Shock.